A Single and Repeat Dose Trial in Participants With Hepatic Impairment
Status:
Recruiting
Trial end date:
2022-09-10
Target enrollment:
Participant gender:
Summary
This study is a a single (open-label) and repeat dose (randomised, placebo controlled) trial
to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in
participants with hepatic impairment (Child Pugh B and Child Pugh C)